For the quarter ending 2025-09-30, TARS made $118,697,000 in revenue. -$12,335,000 in net income. Net profit margin of -10.39%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 118,697,000 | 102,660,000 | 78,335,000 | 45,564,000 |
| Selling, general and administrative | - | - | 84,995,000 | 59,327,500 |
| Research and development | - | - | 14,409,000 | 14,469,500 |
| Cost of sales | - | - | 5,211,000 | 3,290,000 |
| Total operating expenses | 133,226,000 | 124,844,000 | 104,615,000 | 78,063,500 |
| Loss from operations before other income (expense) | -14,529,000 | -22,184,000 | -26,280,000 | -31,052,500 |
| Interest income | 4,114,000 | 4,229,000 | 3,454,000 | 3,382,000 |
| Interest expense | 2,268,000 | 2,240,000 | 2,213,000 | 1,647,500 |
| Realized/unrealized (loss) gain on equity investments | - | - | - | -195,000 |
| Change in fair value of equity warrants issued by licensee | - | - | - | -50,250 |
| Loss on debt extinguishment | 0 | 0 | - | 0 |
| Other income (expense), net | 98,000 | -145,000 | -81,000 | 141,250 |
| Total other income (expense), net | 1,944,000 | 1,844,000 | 1,160,000 | 1,630,500 |
| Loss before income taxes | - | - | - | -28,888,500 |
| Benefit from income taxes | - | - | - | 0 |
| Net loss | -12,585,000 | -20,340,000 | -25,120,000 | -29,422,000 |
| Unrealized gain (loss) on marketable securities and cash equivalents | 250,000 | -46,000 | -94,000 | -114,000 |
| Comprehensive loss | -12,335,000 | -20,386,000 | -25,214,000 | -29,536,000 |
| Net loss per share - basic (usd per share) | -0.3 | -0.48 | -0.64 | -0.79 |
| Net loss per share - diluted (usd per share) | -0.3 | -0.48 | -0.64 | -0.79 |
| Weighted-average shares outstanding - diluted (in shares) | 42,607,717 | 42,360,452 | 39,345,359 | -19,300,331.5 |
| Weighted-average shares outstanding, basic (in shares) | 42,607,717 | 42,360,452 | 39,345,359 | -19,300,331.5 |
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)